Hims & Hers delivered strong Q2 growth, driven by compounded GLP-1 offerings, but faces uncertainty as regulatory and supply ...

Linda Yaccarino has a new job in a vastly different industry weeks after her exit as CEO of X, Elon Musk 's social discourse ...

GLP-1RAs were associated with lower risk for major adverse cardiovascular and cerebrovascular events in MGUS with type 2 diabetes.

Eris Lifesciences to leverage Novo Nordisk's exit and semaglutide patent expiry, with cartridge capacity and diabetes-focused ...

Hims & Hers Health stock fell as much as 5% early Tuesday after the company reported revenue late Monday that fell shy of Wall Street forecasts while maintaining its full-year for ...

Hims & Hers stock (NASDAQ: HIMS) fell approximately 13% in after-hours trading following Q2 results that demonstrated strong ...

Novo Nordisk (NYSE: NVO) stock is testing the patience of buy-and-hold investors. Over the last five years, NVO stock is up more than 200%. However, in the last year, it’s down over 61% and more than ...

Coming off GLP-1 drugs doesn’t have to mean inevitable weight gain. Giulia Crouch asks doctors what you can do to keep it off ...

Aetna’s multi-year margin recovery is a top priority, and CVS is making progress through organizational realignment, ...

Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...